{
  "report_rows": [
    {
      "kpi": "Adj EPS (Q4 FY2026)",
      "prediction": "MISS",
      "answer": "pred ~$3.68 vs. cons $3.767",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Recurring Revenue (Q4 FY2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1,530M vs. cons $1,507M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Closed Sales (Q4 FY2026)",
      "prediction": "MISS",
      "answer": "pred ~$118M vs. cons $135M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2027 Recurring Revenue Growth (FY2027)",
      "prediction": "UNCHANGED",
      "answer": "guide ~5-7% vs. cons ~6.4%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2027 Adj EPS Growth (FY2027)",
      "prediction": "UNCHANGED",
      "answer": "guide ~7-11% vs. cons ~8.9%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Closed Sales Pipeline / Deal Cycle (qualitative)",
      "prediction": "LOWER",
      "answer": "cautious tone, no acceleration signal vs. market normalization expectation",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -3.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -5.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 sell-side trims FY2027 recurring revenue estimates as closed sales miss implies lower backlog entering FY2027; no near-term catalyst to reverse",
  "day5_confidence": "MEDIUM"
}